12.58 USD
+0.08 (+0.64%)
12.58 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to ATXS. ATXS was compared to 525 industry peers in the Biotechnology industry. While ATXS has a great health rating, there are worries on its profitability. ATXS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- ATXS had negative earnings in the past year.
- In the past year ATXS has reported a negative cash flow from operations.
- In the past 5 years ATXS always reported negative net income.
- ATXS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- ATXS has a Return On Assets (-45.62%) which is comparable to the rest of the industry.
- With a decent Return On Equity value of -53.17%, ATXS is doing good in the industry, outperforming 65.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.62% | ||
| ROE | -53.17% | ||
| ROIC | N/A |
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ATXS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ATXS has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, ATXS has more shares outstanding
- There is no outstanding debt for ATXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 6.54 indicates that ATXS is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 6.54, ATXS is in the better half of the industry, outperforming 76.19% of the companies in the same industry.
- ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.54 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- ATXS has a Current Ratio of 10.78. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 10.78, ATXS belongs to the best of the industry, outperforming 84.95% of the companies in the same industry.
- ATXS has a Quick Ratio of 10.78. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 10.78, ATXS belongs to the best of the industry, outperforming 84.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.78 | ||
| Quick Ratio | 10.78 |
3. Growth
3.1 Past
- ATXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.44%, which is quite good.
EPS 1Y (TTM)12.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 7.30% on average over the next years.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-53.66%
EPS Next 2Y-26.06%
EPS Next 3Y-11.95%
EPS Next 5Y7.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- ATXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATXS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ATXS's earnings are expected to decrease with -11.95% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.06%
EPS Next 3Y-11.95%
5. Dividend
5.1 Amount
- ATXS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ASTRIA THERAPEUTICS INC / ATXS FAQ
Can you provide the ChartMill fundamental rating for ASTRIA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to ATXS.
What is the valuation status for ATXS stock?
ChartMill assigns a valuation rating of 0 / 10 to ASTRIA THERAPEUTICS INC (ATXS). This can be considered as Overvalued.
What is the profitability of ATXS stock?
ASTRIA THERAPEUTICS INC (ATXS) has a profitability rating of 1 / 10.
What is the earnings growth outlook for ASTRIA THERAPEUTICS INC?
The Earnings per Share (EPS) of ASTRIA THERAPEUTICS INC (ATXS) is expected to decline by -53.66% in the next year.